Figure 2

CMTC portfolios of 284 breast cancers in the new internal cohort. The 284 breast cancers are grouped by CMTC with their portfolios shown in columns. Rows presented: (A) Tumor receptor status, grade, recurrence and molecular subtypes. The multi-color bars indicate the following: HER2+/TN: HER2+ (human epidermal growth factor receptor 2 positive), deep pink; and TN (triple-negative), dark blue. ER (estrogen receptor): positive, deep pink; negative, empty. Grade: grade 1, dark blue; grade 2, dark orange; and grade 3, deep pink. Recurrence: yes, deep pink; no, empty. The subtype (intrinsic subtype) and PAM50 (prediction analysis of microarray of 50 genes): normal-like, lime; luminal A, blue; luminal B, dark orange; basal-like, dark blue; and Her2+, deep pink. (B) The scores of prognostic gene signatures: TGFβRII (type II TGF-β receptor [9]), 70GS (MammaPrint™ [10]), P53GS (mutated P53 GS [11]), SDPP (stroma-derived prognostic predictor [12]), 37GS (lethal phenotype GS [13]), 76GS (Rotterdam signature [14]), 97GS (genomic grade index [15]); ERGS (estrogen-regulated GS [16]), Proliferation (proliferation metagene GS [17]), IGS (invasiveness GS [18]), ESGS (embryonic stem cell–like GS [19]), and WS (Wound-response GS [20]). (C) The scores of oncogenic signaling pathways. The abbreviation of pathways: STAT3 (signal transducer and activator of transcription 3), EGFR (epidermal growth factor receptor), TTGFβ (transforming growth factor beta), E2F3 (E2F transcriptional factor 3), IFNα (interferon alpha), IFNγ (interferon gamma), E2F1 (E2F transcriptional factor 1), PI3K (phosphatidylinositol 3-kinase), and TNFα (tumor necrosis factor alpha).